Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana (Q34095099)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana |
scientific article |
Statements
1 reference
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana (English)
1 reference
N Fleeman
1 reference
A Bagust
1 reference
A Boland
1 reference
R Dickson
1 reference
Y Dundar
1 reference
M Moonan
1 reference
J Oyee
1 reference
M Blundell
1 reference
H Davis
1 reference
A Armstrong
1 reference
N Thorp
1 reference
1 January 2011
1 reference
1 reference
15
1 reference
42
1 reference
1-93, iii-iv
1 reference
Identifiers
1 reference
1 reference